Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Abstract

Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-gamma) production in the lungs of RSV-infected mice. Its F(ab')(2) component only mediates decreased leukocyte trafficking and IFN-gamma production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.

• Authors: Congrong Miao, Gertrud U Radu, Hayat Caidi, Ralph A Tripp, Larry J Anderson, Lia M Haynes
• Journal: The Journal of general virology (J Gen Virol) Vol. 90 Issue Pt 5 Pg. 1119-1123 (May 2009) ISSN: 0022-1317 [Print] England
• PMID: 19264600 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Viral
• G glycoprotein, Respiratory syncytial virus
• Immunoglobulin Fab Fragments
• Viral Fusion Proteins

Topics

• Animals
• Antibodies, Monoclonal (immunology)
• Antibodies, Viral (immunology)
• Immunoglobulin Fab Fragments (immunology)
• Lung (cytology, pathology)
• Mice
• Mice, Inbred BALB C
• Respiratory Syncytial Virus Infections (immunology, pathology)
• Respiratory Syncytial Viruses (metabolism)
• Time Factors
• Viral Fusion Proteins (immunology)